Abstract
In cartilage regenerative medicine, which is highly expected in the face of our aging society, insulin is the potent factor for culture media. To secure the safety of culture media, we attempted to use medical insulin formulations, and compared their effects on human articular or auricular chondrocytes between regular human insulin (R) and neutral protamine hagedorn insulin (N). In monolayer culture with the media containing either R or N, the cell growth reached approximately 15-fold-increase in 6 days, which showed no significant difference between them. These cells showed the equivalent ability to produce cartilage matrices, both in vitro and in vivo. Also, in the 3D culture of the dedifferentiated chondrocytes, either R or N increased gene expression of type II collagen at 3-4 folds in the combination with other growth factors, compared with basal medium, while insulin could similarly enhance both the redifferentiation and cartilage maturation. The in vitro half-life of each insulin in the presence of chondrocytes neither decreased within 3 days, suggesting little degradation in the culture media, unlike in the body. Although both R and N showed similar biological effects on cultured chondrocytes, we may choose the R for clinical practice because of its pure composition.
Keywords: Chondrocyte, cartilage, tissue engineering, insulin formulation, safety
Current Aging Science
Title: The Effects of Rapid- or Intermediate-Acting Insulin on the Proliferation and Differentiation of Cultured Chondrocytes
Volume: 3 Issue: 1
Author(s): Kumiko Iwata, Yukiyo Asawa, Yuko Fujihara, Yoko Tanaka, Satoru Nishizawa, Takumi Nakagawa, Satoru Nagata, Tsuyoshi Takato and Kazuto Hoshi
Affiliation:
Keywords: Chondrocyte, cartilage, tissue engineering, insulin formulation, safety
Abstract: In cartilage regenerative medicine, which is highly expected in the face of our aging society, insulin is the potent factor for culture media. To secure the safety of culture media, we attempted to use medical insulin formulations, and compared their effects on human articular or auricular chondrocytes between regular human insulin (R) and neutral protamine hagedorn insulin (N). In monolayer culture with the media containing either R or N, the cell growth reached approximately 15-fold-increase in 6 days, which showed no significant difference between them. These cells showed the equivalent ability to produce cartilage matrices, both in vitro and in vivo. Also, in the 3D culture of the dedifferentiated chondrocytes, either R or N increased gene expression of type II collagen at 3-4 folds in the combination with other growth factors, compared with basal medium, while insulin could similarly enhance both the redifferentiation and cartilage maturation. The in vitro half-life of each insulin in the presence of chondrocytes neither decreased within 3 days, suggesting little degradation in the culture media, unlike in the body. Although both R and N showed similar biological effects on cultured chondrocytes, we may choose the R for clinical practice because of its pure composition.
Export Options
About this article
Cite this article as:
Iwata Kumiko, Asawa Yukiyo, Fujihara Yuko, Tanaka Yoko, Nishizawa Satoru, Nakagawa Takumi, Nagata Satoru, Takato Tsuyoshi and Hoshi Kazuto, The Effects of Rapid- or Intermediate-Acting Insulin on the Proliferation and Differentiation of Cultured Chondrocytes, Current Aging Science 2010; 3 (1) . https://dx.doi.org/10.2174/1874609811003010026
DOI https://dx.doi.org/10.2174/1874609811003010026 |
Print ISSN 1874-6098 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-6128 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Separation of Peptides and Proteins by Countercurrent Chromatography
Current Proteomics Lessons from Leptins Molecular Biology: Potential Therapeutic Actions of Recombinant Leptin and Leptin-Related Compounds
Mini-Reviews in Medicinal Chemistry Pancreatic Amylin as a Centrally Acting Satiating Hormone
Current Drug Targets Oxidative Stress Modulation Through Habitual Physical Activity
Current Pharmaceutical Design Inhibitors of 11β-Hydroxylase (CYP11B1) for Treating Diseases Related to Excess Cortisol
Current Medicinal Chemistry Doing the Puzzle of Steroid Hormone Action: Biological Functions, Physiological and Clinical Significance of Plasma Membrane-Residing Glucocorticoid Recognizing Proteins
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Bacterial Toxins: A Hope Towards Angiogenic Ailments
Current Drug Metabolism The Prevalence and Progression of Arterial Calcification in Patients with End-Stage Renal Disease
Vascular Disease Prevention (Discontinued) General Molecular Biology and Architecture of Nuclear Receptors
Current Topics in Medicinal Chemistry Genome-Wide RNAi Longevity Screens in Caenorhabditis elegans
Current Genomics Inhibitors of the PI3K/Akt/mTOR Pathway: New Hope for Breast Cancer Patients
Recent Patents on Anti-Cancer Drug Discovery Editorial:
Current Diabetes Reviews Surgical Strategies for Fertility Preservation in Women with Cancer
Current Women`s Health Reviews γ-Secretase-Regulated Signaling: Notch, APP, and Alzheimers Disease
Current Psychopharmacology Mitochondrial Biogenesis: A Therapeutic Target for Neurodevelopmental Disorders and Neurodegenerative Diseases
Current Pharmaceutical Design Efficacy of Direct-Acting Antiviral Combination Therapy in the Treatment of Hepatitis C Virus Among Kidney Transplant Patients
Anti-Infective Agents Molecular Basis of Antiretroviral Drugs-Associated Long-Term Toxicity: How Bad can Good Drugs Be?
Current Medicinal Chemistry - Anti-Infective Agents Thresholds for Central Blood Pressures and Augmentation Indices - are They Needed and How Far are We in the Process of Their Definition?
Current Hypertension Reviews Stearoyl-CoA Desaturase-1 and the Metabolic Syndrome
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Redox Control of Cardiovascular Homeostasis by Angiotensin II
Current Pharmaceutical Design